Provided by Tiger Fintech (Singapore) Pte. Ltd.

CRISPR Therapeutics AG

54.50
+1.973.75%
Volume:1.88M
Turnover:99.44M
Market Cap:5.19B
PE:-9.76
High:54.60
Open:51.36
Low:51.22
Close:52.53
52wk High:78.48
52wk Low:30.04
Shares:95.30M
Float Shares:90.53M
Volume Ratio:1.84
T/O Rate:2.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.5830
EPS(LYR):-4.3416
ROE:-25.33%
ROA:-13.28%
PB:2.71
PE(LYR):-12.55

Loading ...

Crispr Therapeutics price target raised to $93 from $78 at BofA

TIPRANKS
·
Oct 17

2 Soaring Cathie Wood Stocks to Buy and Hold

Motley Fool
·
Oct 17

CRISPR Therapeutics Plans to Sell Up to $600 Million in Common Stock

Deep News
·
Oct 16

New to Growth Stocks? Here's 1 Every Investor Should Have on Their Radar.

Motley Fool
·
Oct 16

Truist Financial Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)

TIPRANKS
·
Oct 13

4 biotech bargains with realistic upside

LiveWire
·
Oct 13

4 Healthcare Stocks to Buy Now

Motley Fool
·
Oct 12

Crispr Therapeutics AG: Buy Rating Backed by Innovative SyNTase Platform and Promising Preclinical Data

TIPRANKS
·
Oct 11

Crispr Therapeutics Price Target Maintained With a $81.00/Share by Needham

Dow Jones
·
Oct 10

Crispr Therapeutics AG: Promising Advancements in Gene Editing Justify Buy Rating

TIPRANKS
·
Oct 10

Crispr Says CTX460 for Alpha-1 Antitrypsin Deficiency Treatment Shows 'Durable Effects' in Preclinical Studies

MT Newswires Live
·
Oct 10

CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform

GlobeNewswire
·
Oct 10

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

GlobeNewswire
·
Oct 09

AI Biotech Stocks Shined. Ginkgo Up 12%; Recursion And Crispr Up 8%; Tempus And Hims & Hers Up 3%

Tiger Newspress
·
Oct 08

Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead

Motley Fool
·
Oct 08

Crispr Therapeutics to present preclinical data on AATD at ESGCT 2025

TIPRANKS
·
Oct 01

CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

GlobeNewswire
·
Oct 01

Got $200? 2 Healthcare Stocks to Buy and Hold Forever

Motley Fool
·
Oct 01

Could This Beaten-Down Stock Help You Become a Millionaire?

Motley Fool
·
Sep 30

You're just getting scraps from the stock market. Here's where the big money is made.

Dow Jones
·
Sep 28